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Oxyphenbutazone and Flufenamic Acid in the
Treatment of Osteo-arthritis of the Knee
A DOUBLE-BLIND TRIAL COMPARISON
G. H. ERDMANN
SUMMARY
Patients suffering from osteo-arthritis of the knee were
admitted to a double-blind trial comparing the efficacy
and tolerability of oxyphenbutazone (Tanderil) and flu-
fenamic acid. Objective and subjective parameters were
measured to assess the anti-inflammatory activity of the
trial medication. Tolerability and side-effects were evalu-
ated by subjective statement.
Fifty patients entered the trial. On the 7th day of
treatment oxyphenbutazone was found to be significantly
superior to flufenamic acid in improving stiffness and the
patient's feeling of well-being. Oxyphenbutazone signifi-
cantly reduced pain on the 3rd day of treatment, com-
pared with flufenamic acid. No serious side-effects were
encountered.
S. Air. Med. J., 48, 947 (1974).
Clinical trials have shown oxyphenbutazone (Tanderil) to
be orally effective in a wide variety of rheumatic disorders
and other inflammatory conditions. It possesses markedly
rapid anti-inflammatory and antipyretic activity. Although
oxyphenbutazone has little direct analgesic action, its
ability to reduce pain is thought to be due to its anti-
inflammatory activity. These properties prompted this
trial with oxyphenbutazone in a series of patients suffering
from osteo-arthritis of the knee.
PATIENTS AND METHODS
Fifty patients suffering from osteo-arthritis of the knee
were admitted to a between-patient double-blind trial,
comparing the efficacy and tolerability of oxyphenbutazone
and flufenamic acid. Patients with a present or past history
of dyspepsia, peptic ulcer, haemorrhagic diathesis, hyper-
sensitivity to the trial medications, and leucopenia, were
excluded. Each patient was treated for 10 days with
either oxyphenbutazone or flufenamic acid. Both medi-
cations were presented in identical capsules in a dose of
200 mg t.i.d. Objective and subjective parameters were
measured to assess the anti-inflammatory activity of the
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trial medication. Tolerability and side-effects were
evaluated by subjectiv~ statement.
Assessments were carried out, pre-treatment (after a
wash-out period of 1 week for those patients on previous
antirheumatic therapy), and subsequently on days 3, 7 and
10. The index of response to treatment was measured by
assessing the following 5 parameters on a 5-point scale:
pain, severity of stiffness, early morning stiffness and
time taken to recover, mobility and over-all feeling of
well-being. Tenderness was assessed using a 4-point scale.
In addition the patients themselves assessed pain and
feeling of well-being using a visual analogue scale.' Joint
circumference, effusions (flexion and extension) and ery-
throcyte sedimentation rate were measured, the latter only
before and after the trial.
RESULTS
Fifty patients completed the trial and were equally
distributed in oxyphenbutazone and flufenamic subsamples,
statistically homogeneous in respect to age, sex, duration
and severity of illness.
Analysis of the pain scores by means of the Kruskal-
Wallis' test showed that there was no significant difference
between the subsamples pre-treatment, or on days 3, 7
and 10, as scored by the patients. However, application of
this test on the investigator's scores showed that oxyphen-
butazone was superior to flufenamic acid on day 3 at the
5% level, but no differences were observed pre-treatment
or on days 7 and 10.
A patient's visual analogue scale was also used to
estimate the response to the treatments in respect of pain.
Analysis of covariance on these pain scores showed that
there was no significant difference between the treatments.
However, the rate of improvement was highly significant
for both subsamples and followed a linear trend with
time.
The effect of treatment on the severity of stiffness was
measured independently by both investigator and patients.
Analysis by means of the Kruskal-Wallis test showed
that no statistically significant difference between the
treatments was observed on days 3 and 10. A significant
difference at the 5°0 level was found in favour of
oxyphenbutazone on day 7 for both assessments.
The assessment of early morning stiffness and rate of
improvement was made by the patient on rising, and
subsequently every half-hour for 4 hours. The scores were


























summated for each day to give a total stiffness score,
and submitted to analysis of covariance, from which it
was found that both treatments produced a significant
improvement over the trial period.
Analysis of the results of the investigator's assessment
of tenderness, mobility, effusion, and joint size (of the
worst knee), indicated that there was no significant
difference between the treatments, both giving improve-
ment.
Erythrocyte sedimentation rate readings were taken pre-
treatment and on day 10. No statistically significant
differences were found between the treatments at either
assessment or between the assessments pre-treatment or
on day 10.
An over-all assessment of efficacy was made indepen-
dently by the investigator and the patient. Analysis of
the results of the patient's assessment by the Kruskal-
Wall is test showed that oxyphenbutazone was significantly
superior on day 7 only, and analysis of the results of
the investigator's assessment failed to show any significant
differences.
The patients also recorded their over-all opinion of
treatment effect on a visual analogue scale; analysis of
covariance showed no significant difference between the
treatments but a highly significant linear improvement for
both with time.
Adverse Reaction and Side-Effects
No drop-outs occurred. Three patients treated WIth
oxyphenbutazone suffered minor side-effects, although 2
of them had had these symptoms before treatment.
One patient in the flufenamic acid treatment group showed
minor side-effects. Table I gives details of the side-effects
encountered.
CONCLUSION
Oxyphenbutazone significantly improved stiffness on day
7 (patient and observer assessment), pain (patient assess-
ment) on the 3rd day, and over-all feeling of well-being
(patient assessment) on day 7, indicating a more rapid
response of these parameters to oxyphenbutazone.
Comparing oxyphenbutazone and flufenamic acid, the
latter could in no way be found to be superior. No
serious side-effects were encountered and of the three
patients suffering from minor side-effects, 2 had shown
symptoms before treatment.
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